Drug Profile
AZD 6714
Alternative Names: AZD6714Latest Information Update: 01 Aug 2011
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antihyperglycaemics
- Mechanism of Action Glucokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2011 Discontinued - Phase-I for Type-2 diabetes mellitus in Sweden (PO)
- 17 Apr 2009 Phase I clinical trials in type 2 diabetes mellitus in Sweden (PO)